Cystic Fibrosis is a congenital genetic disease, inherited or due to de novo mutation, affecting secretions on mucous surfaces of the body, causing symptoms particularly from the airways and the GI tract. The sufferers develop acute and chronic infections of the lungs, resulting in structural damage and decreasing lung function.
Aggressive treatment with intravenous antibiotics and with inhaled substances improved the prognosis during the last few decades of last century, novel treatment modalities attacking the folding of the membrane protein secondary to the genetic defect hold the promise of further improvement.
CF is treated by pediatricians and infectious diseases specialists. The SIG will be a common forum for exchanging ideas and experiences regarding immunological characterization and effect of interventions.
To formulate projects along the guidelines of the PERSIMUNE collaboration, taking into account the genetic diversity of the CF patient population, and the diversity in immunological deficiency and treatment response.